CED Clinical Trials

2,648 recruitingLast updated: June 18, 2026

There are 2,648 actively recruiting ced clinical trials across 88 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Shanghai, Shanghai Municipality, China, New York, New York, United States. Updated daily from ClinicalTrials.gov.


CED Trials at a Glance

2,648 actively recruiting trials for ced are listed on ClinicalTrialsFinder across 6 cities in 88 countries. The largest study group is Phase 1 with 1,027 trials, with the heaviest enrollment activity in Houston, Shanghai, and New York. Lead sponsors running ced studies include National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Fudan University.

Treatments under study

About CED Clinical Trials

Looking for clinical trials for CED? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new CED trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about CED clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 2,648 trials

Recruiting
Phase 1Phase 2

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Metastatic NUT CarcinomaUnresectable NUT CarcinomaAdvanced NUT Carcinoma
National Cancer Institute (NCI)36 enrolled5 locationsNCT05019716
Recruiting
Phase 1

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Metastatic Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma
Alnylam Pharmaceuticals158 enrolled23 locationsNCT06600321
Recruiting
Phase 3

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Advanced Endometrial CarcinomaRecurrent Endometrial Carcinoma
National Cancer Institute (NCI)255 enrolled218 locationsNCT07198074
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Metastatic Soft Tissue SarcomaMetastatic LeiomyosarcomaAdvanced Soft Tissue Sarcoma+5 more
National Cancer Institute (NCI)74 enrolled1 locationNCT06498648
Recruiting
Phase 1Phase 2

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca152 enrolled103 locationsNCT06996782
Recruiting
Phase 2

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)88 enrolled36 locationsNCT05327010
Recruiting
Phase 1

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI)48 enrolled1 locationNCT06364410
Recruiting
Phase 2Phase 3

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled372 locationsNCT06203600
Recruiting
Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Locally Advanced Cervical Adenocarcinoma+5 more
National Cancer Institute (NCI)336 enrolled271 locationsNCT07061977
Recruiting
Phase 3

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI)304 enrolled318 locationsNCT06096844
Recruiting
Phase 2

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Metastatic Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)500 enrolled27 locationsNCT06311214
Recruiting
Phase 1

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)66 enrolled6 locationsNCT05687136
Recruiting
Phase 2

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

Metastatic Alveolar Soft Part SarcomaAdvanced Soft Tissue SarcomaAdvanced Alveolar Soft Part Sarcoma+2 more
National Cancer Institute (NCI)27 enrolled13 locationsNCT05333458
Recruiting
Phase 3

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Stage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Non-Squamous Non-Small Cell Carcinoma+2 more
National Cancer Institute (NCI)300 enrolled603 locationsNCT04181060
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Not Applicable

High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial

Advanced MelanomaSkin CancerMelanoma (Skin)
Fred Hutchinson Cancer Center40 enrolled2 locationsNCT06298734
Recruiting
Phase 1

Study of GS-5319 in Adults With Solid Tumors

Advanced Solid Tumor
Gilead Sciences178 enrolled10 locationsNCT07128303
Recruiting
Phase 1

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

Advanced Malignancies
Novartis Pharmaceuticals24 enrolled3 locationsNCT07340190
Recruiting
Phase 1Phase 2

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Advanced Solid Tumors
Nutshell Therapeutics (Shanghai) Co., LTD.220 enrolled2 locationsNCT07060989
Recruiting
Phase 1Phase 2

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced/Metastatic Solid Tumors
Crescent Biopharma, Inc.290 enrolled17 locationsNCT07335497